Drug intelligence / Profile preview

anti-integrin alpha3 activating antibody

Development stage: Preclinical
Lead developer: Allosite Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

The anti-integrin alpha3 activating antibody is a novel, first-in-class allosteric agonist monoclonal antibody designed to target and activate the integrin alpha-3 beta-1 (α3β1) heterodimer. Developed by Allosite Therapeutics (formerly 149 Bio), this therapeutic candidate is engineered to enhance podocyte adhesion to the glomerular basement membrane (GBM) and stabilize the actin cytoskeleton. By promoting podocyte retention and preventing cellular detachment, the antibody aims to protect against glomerular injury and reduce albuminuria in progressive kidney diseases, such as focal segmental glomerulosclerosis (FSGS) and chemotherapy-induced nephrotoxicity.

Other names: anti-integrin alpha3 antibodyanti-integrin α3 antibodyintegrin alpha3beta1 activating antibodyintegrin alpha3beta1 agonist antibodyintegrin α3β1 activating antibodyintegrin α3β1 agonist antibody

Targets

Integrin (Integrin family)α3β1 (Integrin alpha 3 beta 1)

Beyond the preview

Go deeper on anti-integrin alpha3 activating antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-integrin alpha3 activating antibody.